Akebia Therapeutics (AKBA) Stock Analysis & Winston Score

Akebia Therapeutics is a biopharmaceutical company focused on treating anemia caused by chronic kidney disease (CKD). Its main product is Vafseo (vadadustat), an oral pill that helps the body produce more red blood cells. The drug targets patients on dialysis and those with CKD who are not yet on dialysis, competing against injectable treatments that have dominated this market for decades. Akebia earns revenue primarily through product sales of Vafseo in the United States, where it received FDA approval in 2024, as well as through licensing and collaboration agreements with partners in other regions. The company is small, with a market cap around $400 million, and its main competitive edge is offering an oral alternative to injectable anemia drugs made by much larger rivals. The key growth driver is expanding Vafseo's commercial uptake among nephrologists and dialysis centers, while the main risk is that gaining market share against entrenched injectable therapies with established reimbursement and prescribing habits will be difficult and slow.